Biosimilars Adoption: Recognizing and Removing the RoadBlocks

References

• Tichy EM, Hoffman JM, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022;79(14):1158–1172. PMID: 35385103; PMCID: PMC9383648. doi:10.1093/ajhp/zxac102
   PubMed Web of Science ®Google Scholar
• Cicchiello A, Gustafsson L. Brand-Name Drug Prices: The Key Driver of High Pharmaceutical Spending in the US. - An International Comparison of Prescription Drug Spending and Costs. New York, NY: Commonwealth Fund; 2021.
   Google Scholar
• Conti RM, Berndt ER. Four facts concerning competition in US. generic prescription drug markets. Int J Econ Bus. 2020;27(1):27–48. doi:10.1080/13571516.2019.1654324
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office. Research and development in the pharmaceutical industry. Available from: https://www.cbo.gov/publication/57126. Accessed March 31, 2023.
   Google Scholar
• Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. J Am Med Assoc. 2020;323(9):844–853. doi:10.1001/jama.2020.1166
   PubMed Web of Science ®Google Scholar
• IQVIA Global Trends in R&D. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023. Accessed March 31, 2023.
   Google Scholar
• Title VII—improving access to innovative medical therapies subtitle a—biologics price competition and innovation. Available from: https://www.fda.gov/media/78946/download. Accessed March 31, 2023.
   Google Scholar
• CMS. 2023 ASP Drug Pricing Files Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2023-asp-drug-pricing-files. Accessed March 31, 2023.
   Google Scholar
• Babaeipour V, Khanchezar S, Mofid MR, et al. Efficient process development of recombinant human granulocyte colony-stimulating factor (rh-GCSF) production in Escherichia coli. Iran Biomed J. 2015;19(2):102–110. PMID: 25864815; PMCID: PMC4412921. doi:10.6091/ibj.1338.2015
   PubMedGoogle Scholar
• WHO. Call for consultant on monoclonal antibodies for infectious diseases. Available from: https://www.who.int/news-room/articles-detail/call-for-consultant-on-monoclonal-antibodies-for-infectious-diseases. Accessed March 31, 2023.
   Google Scholar
• Eri Amasawa, Hiroaki Kuroda, Kozue Okamura, Sara Badr, and Hirokazu Sugiyama, Cost–Benefit Analysis of Monoclonal Antibody Cultivation Scenarios in Terms of Life Cycle Environmental Impact and Operating Cost. ACS Sustainable Chemistry & Engineering 2021 9 (42), 14012-14021. DOI: 10.1021/acssuschemeng.1c01435 1. . Accessed March 31, 2023.
   Google Scholar
• Humira Prices, Coupons and Patient Assistance Programs Available from: https://www.drugs.com/price-guide/humira. Accessed March 31, 2023.
   Google Scholar
• McKinsey Three imperatives for research in biosimilars. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/three-imperatives-for-r-and-d-in-biosimilars. Accessed March 31, 2023.
   Google Scholar
• FDA. Biosimilar science and research. Available from: https://www.fda.gov/drugs/biosimilars/biosimilars-science-and-research. Accessed July 10, 2022.
   Google Scholar
• FDA. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Guidance for Industry. Available from: https://www.fda.gov/media/159261/download. Accessed March 31, 2023.
   Google Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi:10.1038/s41586-021-03819-2
   PubMed Web of Science ®Google Scholar
• Callaway, E. News July 2022 ‘The entire protein universe’: AI predicts shape of nearly every known protein DeepMind’s AlphaFold tool has determined the structures of around 200 million proteins.. . Available from: https://www.nature.com/articles/d41586-022-02083-2. Accessed March 31, 2023.
   Google Scholar
• AlphaFoldAphaFold Protein Structure Database.. Available from: https://alphafold.ebi.ac.uk/. Accessed March 31, 2023.
   Google Scholar
• Niazi SK. US patent application. Available from: https://patents.google.com/patent/US20180024137A1/en?oq=US20180024137A1. Accessed March 31, 2023.
   Google Scholar
• Coghlan J, Benet A, Kumaran P, et al. Streamlining the characterization of disulfide bond shuffling and protein degradation in IgG1 biopharmaceuticals under native and stressed conditions. Front Bioeng Biotechnol. 2022;10:862456. PMID: 35360407; PMCID: PMC8963993. doi:10.3389/fbioe.2022.862456
   PubMed Web of Science ®Google Scholar
• Stanford University Course. Completed biosimilar trials with results. Available from: https://clinicaltrials.gov/ct2/results?term=biosimilar&age_v=&gndr=&type=&rslt=With&Search=Apply. Accessed March 31, 2023.
   Google Scholar
• Particle Sentry AI: Quality Control in Drug Product Manufacturing Available from: https://www.semitorr.com/specialties/particle-sentry-ai-quality-control-in-drug-product-manufacturing/. Accessed March 31, 2023.
   Google Scholar
• FDA: Artificial Intelligence/Machine Learning Assisted Image Analysis for Characterizing Biotherapeutics Available from: https://www.fda.gov/drugs/regulatory-science-action/artificial-intelligencemachine-learning-assisted-image-analysis-characterizing-biotherapeutics?utm_medium=email&utm_source=govdelivery. Accessed March 31, 2023.
   Google Scholar
• Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Assessment of availability, clinical testing, and US food and drug administration review of biosimilar biologic products. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.3997
   PubMed Web of Science ®Google Scholar
• Niazi SK. Biosimilars: a futuristic fast-to-market advice to developers. Expert Opin Biol Ther. 2022;22(2):149–155. PMID: 34913776. doi:10.1080/14712598.2022.2020241
   PubMed Web of Science ®Google Scholar
• Li J, Florian J, Campbell E, et al. Advancing biosimilar development using pharmacodynamic biomarkers in clinical pharmacology trials. Clin Pharmacol Ther. 2020;107:40–42. doi:10.1002/cpt.1653
   PubMed Web of Science ®Google Scholar
• Completed biosimilar trials with results. https://clinicaltrials.gov/ct2/results?term=biosimilar&age_v=&gndr=&type=&rslt=With&Search=Apply. Available from: https://clinicaltrials.gov/ct2/results?term=biosimilar&age_v=&gndr=&type=&rslt=With&Search=Apply. Accessed March 31, 2023.
   Google Scholar
• Biosimilar Clinical Trials in peer-reviewed articles as reported in PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/?term=biosimilar+clinical+trial. Accessed March 31, 2023.
   Google Scholar
• Niazi S. Scientific rationale for waiving clinical efficacy testing of biosimilars. Drug Des Devel Ther. 2022;16:2803–2815. PMID: 36043044; PMCID: PMC9420434. doi:10.2147/DDDT.S378813
   PubMed Web of Science ®Google Scholar
• MHRA. Biosimilar guidance. Available from: https://www.gov.uk/government/publications/guidance-on-The-licensing-of-biosimilar-products/guidance-on-The-licensing-of-biosimilar-products. Accessed June 8, 2022.
   Google Scholar
• Chiu K, Racz R, Burkhart K, et al. New science, drug regulation, and emergent public health issues: the work of FDA’s division of applied regulatory science. Front Med. 2023;9:1109541. doi:10.3389/fmed.2022.1109541
   Web of Science ®Google Scholar
• US Congress. BPCIA. Available from: https://www.congress.gov/bill/111th-congress/house-bill/3590. Accessed March 31, 2023.
   Google Scholar
• Van de Wiele VL, Kesselheim AS, Sarpatwari A. Barriers to US biosimilar market growth: lessons from biosimilar patent litigation. Health Aff. 2021;40(8):1198–1205. Erratum in: Health Aff (Millwood). 2021 Oct;40(10):1671.PMID: 34339242. doi:10.1377/hlthaff.2020.02484
   Web of Science ®Google Scholar
• US Congress H.R.2884 - affordable prescriptions for patients through improvements to patent litigation act. Available from: https://www.congress.gov/bill/117th-congress/house-bill/2884. Accessed March 31, 2023.
   Google Scholar
• Niazi SK. Reinventing commercial biomanufacturing. Available from: https://www.europeanpharmaceuticalreview.com/article/77395/reinventing-commercial-biomanufacturing/. Accessed March 31, 2023.
   Google Scholar
• FDA Press Announcement. FDA and FTC announce new efforts to further deter anticompetitive business practices. Available from: https://www.fda.gov/news-events/press-announcements/fda-and-ftc-announce-new-efforts-further-deter-anti-competitive-business-practices-support. Accessed March 23, 2022.
   Google Scholar
• FDA. Notifies amgen of branding its product neulasta. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-notifies-amgen-misbranding-its-biological-product-neulasta-due-false-or-misleading-promotional. Accessed April 4, 2022.
   Google Scholar
• Whitehouse Announcement Presidential order on promoting competition in the American economy. Available from: https://www.whitehouse.gov/briefing-room/presidential-actions/2021/07/09/executive-order-on-promoting-competition-in-The-american-economy/. Accessed March 23, 2022.
   Google Scholar
• US Senate. Advancing education on biosimilars act. Available from: https://www.cassidy.senate.gov/imo/media/doc/AdvancingEducationonBiosimilarsAct.pdf. (Accessed March 23, 2022.
   Google Scholar
• US Congress. Star rating for biosimilars act. Available from: https://www.congress.gov/bill/117th-congress/house-bill/2855?q=%7B%22search%22%3A%5B%22Star+Rating+for+Biosimilars+Act%22%2C%22Star%22%2C%22Rating%22%2C%22for%22%2C%22Biosimilars%22%2C%22Act%22%5D%7D&s=1&r=1. (Accessed April 4, 2022.
   Google Scholar
• US Congress. H.R.2815—BIOSIM act. Available from: https://www.congress.gov/bill/117th-congress/house-bill/2815/text?r=1&s=1. Accessed March 23, 2022.
   Google Scholar
• US Congress. Preserve access to Af3 fordable generics and biosimilars act. Available from: https://www.congress.gov/117/bills/s1428/BILLS-117s1428rs.pdf. Accessed March 23, 2022.
   Google Scholar
• Niazi SK. The inflation reduction act: a boon for the generic and biosimilar industry. J Clin Pharm Ther. 2022;47(11):1738–1751. PMID: 36207987. doi:10.1111/jcpt.13783
   PubMed Web of Science ®Google Scholar
• US Congress S.5002 - FDA modernization act 2.0. 117th Congress (2021–2022). Available from: https://www.congress.gov/bill/117th-congress/senate-bill/5002/text. Accessed March 31, 2023.
   Google Scholar
• FDA News Release. Withdraws draft guidance for industry: statistical approaches to evaluate analytical similarity. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-withdraws-draft-guidance-industry-statistical-approaches-evaluate-analytical-similarity. Accessed March 31, 2023.
   Google Scholar
• Forbes Magazine. Scientist invented a new pathway to approve biosimilars, and the FDA is listening. Available from: https://www.forbes.com/sites/nicolefisher/2018/07/25/one-mans-mission-to-fix-The-fdas-biosimilar-problem/?sh=67e656742380. Accessed March 31, 2023.
   Google Scholar
• FDA. Clinical immunogenicity considerations for biosimilar and interchangeable insulin products. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-immunogenicity-considerations-biosimilar-and-interchangeable-insulin-products. Accessed March 31, 2023.
   Google Scholar
• FDA. Theragrastim/Releuko approval package. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761082Orig1s000MedR.pdf. Accessed March 31, 2023.
   Google Scholar
• FDA: Innovation and Regulatory Science Available from: https://www.fda.gov/vaccines-blood-biologics/science-research-biologics/innovation-and-regulatory-science. Accessed March 31, 2023.
   Google Scholar
• FDA Innovation and Regulatory Incentives. Available from: https://www.fda.gov/vaccines-blood-biologics/science-research-biologics/innovation-and-regulatory-science. Accessed March 31, 2023.
   Google Scholar
• FDA Grant awarded under BsuFA. FDA biosimilars. Available from: https://www.grants.gov/web/grants/search-grants.html?keywords=fda%20biosimilar. Accessed March 31, 2023.
   Google Scholar
• Press Release US Senate. Senator Lee introduces bill to remove interchangeability of biosimilars. Available from: https://www.lee.senate.gov/2022/11/sen-lee-introduces-biosimilar-red-tape-elimination-act. Accessed March 31, 2023.
   Google Scholar
• Niazi SK. No two classes of biosimilars: urgent advice to the US congress and the FDA. J Clin Pharm Ther. 2022;47(9):1352–1361. PMID: 35869625. doi:10.1111/jcpt.13743
   PubMed Web of Science ®Google Scholar
• EMA. Biosimilar Medicines Can be Changed Available from: https://www.ema.europa.eu/en/news/biosimilar-medicines-can-be-interchanged. Accessed March 31, 2023.
   Google Scholar
• MHRA, Guidance on the licensing of biosimilar products. https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products Available from: https://www.gov.uk/government/publications/guidance-on-The-licensing-of-biosimilar-products/guidance-on-The-licensing-of-biosimilar-products. Accessed March 31, 2023.
   Google Scholar
• News Release. Eli LIlly Company. Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-cuts-insulin-prices-70-and-caps-patient-insulin-out-pocket. Accessed March 31, 2023.
   Google Scholar
• OECD Data. Pharmaceutical Spending Available from: https://data.oecd.org/healthres/pharmaceutical-spending.htm. Accessed March 31, 2023.
   Google Scholar
• US Congress. Congressional Committee Reports mentioning PBMs. Available from: https://www.congress.gov/bill/118th-congress/senate-bill/127/all-info. Accessed March 31, 2023.
   Google Scholar
• US Congress. Pharmacy Benefit Manager Transparency Act of 2023 Available from: https://www.congress.gov/search?q=%7B%22source%22%3A%5B%22comreports%22%5D%2C%22search%22%3A%22PBM%22%7D. Accessed March 31, 2023.
   Google Scholar
• US Congress. Pharmacy Benefit Manager Transparency Act of 2023 Available from: https://www.congress.gov/search?q=%7B%22source%22%3A%5B%22legislation%22%2C%22comreports%22%5D%2C%22search%22%3A%22PBM%22%7D. Accessed March 31, 2023.
   Google Scholar
• News Release. Civica to Manufacture and Distribute Affordable Insulin Available from: https://civicarx.org/. Accessed March 31, 2023.
   Google Scholar
• News release. Insulin is way too expensive. California has a solution: Make its own. Available from: https://www.vox.com/policy-and-politics/23574178/insulin-cost-california-biden-medicare-coverage. Accessed March 31, 2023.
   Google Scholar
• Mark Cuban Cost-plus Drug Company Available from: https://costplusdrugs.com/. Accessed March 31, 2023.
   Google Scholar
• Ferreri, D. Policy Recommendations for Improving Biosimilar Uptake in Belgium Mar 11, 2023 Available from: https://www.centerforbiosimilars.com/view/policy-recommendations-for-improving-biosimilar-uptake-in-belgium. Accessed March 31, 2023.
   Google Scholar
• Andrew W. Mulcahy, “Biosimilar Drugs Could Generate $38.4 Billion in Savings Over Five Years. RAND Corporation; 2022.
   Google Scholar
• Press Release. Organon Foresees US Adalimumab Discounts Hitting 80%-90% CEO Suggests Heavy Competition Will Lead To Steep Price Cuts By 2025-2026 Available from: https://generics.pharmaintelligence.informa.com/GB152419/Organon-Foresees-US-Adalimumab-Discounts-Hitting-8090. Accessed March 31, 2023.
   Google Scholar
• Barclays Bank. U.S. Specialty pharmaceuticals, Sunday soliloquies in spec pharma - can biosimilars pricing head the generics way? Equity research healthcare. One of the more distinctive; 2023.
   Google Scholar
• Podcast: Panelists Suggest More Groundwork Is Needed for Indian Biologics to Podcast. Achieve Global Market Access Available from: https://www.centerforbiosimilars.com/view/part-1-panelists-suggest-more-groundwork-is-needed-for-indian-biologics-to-achieve-global-market-access. Accessed March 31, 2023.
   Google Scholar
• Indian Biosimilar Standards: A Work in Progress Apr 5, 2021 Deana Ferreri, PhD Paul Cornes, BM, BCH, MA, MRCP, FRCR Available from: https://www.centerforbiosimilars.com/view/part-2-panelists-advise-patterning-guidelines-on-international-standards. Accessed March 31, 2023.
   Google Scholar
• Column: India Struggles to Meet International Biologics Standards Apr 10, 2021 Paul Cornes, BM, BCH, MA, MRCP, FRCR Available from: https://www.centerforbiosimilars.com/view/column-india-struggles-to-meet-international-biologics-standards. Accessed March 31, 2023.
   Google Scholar
• Indian Biosimilar Standards: A Work in Progress Apr 5, 2021 Deana Ferreri, PhD Available from: https://www.centerforbiosimilars.com/view/indian-biosimilar-standards-a-work-in-progress. Accessed March 31, 2023.
   Google Scholar
• CDSCO India. GUIDELINES ON SIMILAR BIOLOGICS: Regulatory Requirements for Marketing Authorization in India, 2016 Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadAlertsFiles/BiosimilarGuideline2016.pdf. Accessed March 31, 2023.
   Google Scholar
• Yang J. Study on the purple book system in the United States and discussion on the necessity and feasibility of building the “biologics listed product catalogue collection” in China. Chin Pharm Aff. 2019;33:966–971.
   Google Scholar
• Yang J, Zhao X, Li J, et al. Creating China’s biosimilar drugs regulatory system: a calculated approach. Front Pharmacol. 2022;13:815074. PMID: 35185570; PMCID: PMC8848751. doi:10.3389/fphar.2022.815074
   PubMed Web of Science ®Google Scholar
• Eye on Pharma: Good News, Bad News for Alvotech; EpiVax Secures FDA Grant for Biosimilar Testing Sep 12, 2022 Skylar Jeremias https://www.centerforbiosimilars.com/view/eye-on-pharma-good-news-bad-news-for-alvotech-epivax-secures-fda-grant-for-biosimilar-testing Available from: https://www.centerforbiosimilars.com/view/eye-on-pharma-good-news-bad-news-for-alvotech-epivax-secures-fda-grant-for-biosimilar-testing. Accessed March 31, 2023.
   Google Scholar
• EMA. Centrally approved biosimilars. Available from: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar. Accessed June 8, 2022.
   Google Scholar
• US Congress. Title VII—improving access to innovative medical therapies subtitle a—biologics price competition and innovation. US Congress. Available from: https://www.fda.gov/media/78946/download. Accessed March 23, 2022.
   Google Scholar
• Industry Association: Biosimilars Council. Available from: https://biosimilarscouncil.org/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Association for affordable medicines. Available from: https://accessiblemeds.org/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: International Generics and Biosimilars Association. Available from: https://www.igbamedicines.org/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Biologics and biosimilars collective intelligence consortium. Available from: https://www.bbcic.org/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: British Biosimilar Council. Available from: https://britishbiosimilars.co.uk/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Generic and Biosimilars Association. Available from: https://www.gbma.com.au/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Medicines for Europe. Available from: https://www.medicinesforeurope.com/biosimilar-medicines/. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Danish Generic and Biosimilars Medicines Industry Association Available from: http://www.igldk.dk/english-about. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Biosimilars Canada. Available from: https://biosimilarscanada.ca. Accessed March 31, 2023.
   Google Scholar
• Industry Association: Biotechnology Innovation Organization. Available from: http://www.bio.org. Accessed March 31, 2023.
   Google Scholar
• McKinsey. Inflection point for biosimilars. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars. Accessed March 31, 2023.
   Google Scholar
• Niazi SK. Obstacles to success for biosimilars in the US market. Available from: https://www.europeanpharmaceuticalreview.com/article/70987/obstacles-success-biosimilars-us-market/. Accessed March 31, 2023.
   Google Scholar